PRESS RELEASE
News
-
-
PRESS RELEASE
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Abivax announces significant improvements in quality of life for patients with ulcerative colitis in Phase 3 ABTECT induction trials of Obefazimod, incorporating patient-reported outcomes data -
-
-
-
-
-
-
-
